RETRACTION article

Front. Pharmacol., 25 March 2025

Sec. Ethnopharmacology

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1596508

Retraction: Lycorine displays potent antitumor efficacy in colon carcinoma by targeting STAT3

This article is a retraction of:

  1. RETRACTED: Lycorine Displays Potent Antitumor Efficacy in Colon Carcinoma by Targeting STAT3

    1. Read original article
Frontiers Editorial Office Frontiers Editorial Office*

A Retraction of the Original Research Article
Lycorine Displays Potent Antitumor Efficacy in Colon Carcinoma by Targeting STAT3

by Wu S, Qiu Y, Shao Y, Yin S, Wang R, Pang X, Ma J, Zhang C, Wu B, Koo S, Han L, Zhang Y, Gao X, Wang T and Yu H (2018). Front. Pharmacol. 9:881. doi: 10.3389/fphar.2018.00881

The journal retracts the August 8 2018 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable, and the article has been retracted.

The authors did not provide a response to this retraction.

Citation: Frontiers Editorial Office (2025) Retraction: Lycorine displays potent antitumor efficacy in colon carcinoma by targeting STAT3. Front. Pharmacol. 16:1596508. doi: 10.3389/fphar.2025.1596508

Received: 19 March 2025; Accepted: 19 March 2025;
Published: 25 March 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.